vs
Side-by-side financial comparison of Smith Douglas Homes Corp. (SDHC) and Stoke Therapeutics, Inc. (STOK). Click either name above to swap in a different company.
Smith Douglas Homes Corp. is the larger business by last-quarter revenue ($260.4M vs $158.6M, roughly 1.6× Stoke Therapeutics, Inc.). Stoke Therapeutics, Inc. runs the higher net margin — 71.2% vs 1.4%, a 69.8% gap on every dollar of revenue. On growth, Stoke Therapeutics, Inc. posted the faster year-over-year revenue change (3661.1% vs -9.4%). Stoke Therapeutics, Inc. produced more free cash flow last quarter ($131.7M vs $8.7M).
Smith & Wesson Brands, Inc. (S&W) is an American firearm manufacturer headquartered in Maryville, Tennessee, United States.
Stoke Therapeutics, Inc. is a clinical-stage biotechnology company developing innovative RNA-targeted therapies for severe rare genetic diseases. Its lead candidates address unmet needs for Dravet syndrome, a rare epilepsy, and other neurological monogenic disorders, serving patients across North America and global markets.
SDHC vs STOK — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2025
| Metric | | |
|---|---|---|
| Revenue | $260.4M | $158.6M |
| Net Profit | $3.5M | $112.9M |
| Gross Margin | 19.9% | — |
| Operating Margin | 6.5% | 70.2% |
| Net Margin | 1.4% | 71.2% |
| Revenue YoY | -9.4% | 3661.1% |
| Net Profit YoY | -14.3% | 528.0% |
| EPS (diluted) | $0.39 | $1.90 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $260.4M | — | ||
| Q3 25 | $262.0M | — | ||
| Q2 25 | $223.9M | — | ||
| Q1 25 | $224.7M | $158.6M | ||
| Q4 24 | $287.5M | $22.6M | ||
| Q3 24 | $277.8M | — | ||
| Q2 24 | $220.9M | — | ||
| Q1 24 | $189.2M | — |
| Q4 25 | $3.5M | — | ||
| Q3 25 | $2.1M | — | ||
| Q2 25 | $2.4M | — | ||
| Q1 25 | $2.7M | $112.9M | ||
| Q4 24 | $4.1M | $-10.5M | ||
| Q3 24 | $5.3M | — | ||
| Q2 24 | $3.6M | — | ||
| Q1 24 | $3.0M | — |
| Q4 25 | 19.9% | — | ||
| Q3 25 | 21.0% | — | ||
| Q2 25 | 23.2% | — | ||
| Q1 25 | 23.8% | — | ||
| Q4 24 | 25.5% | — | ||
| Q3 24 | 26.5% | — | ||
| Q2 24 | 26.7% | — | ||
| Q1 24 | 26.1% | — |
| Q4 25 | 6.5% | — | ||
| Q3 25 | 6.6% | — | ||
| Q2 25 | 7.7% | — | ||
| Q1 25 | 8.7% | 70.2% | ||
| Q4 24 | 10.4% | -60.4% | ||
| Q3 24 | 14.2% | — | ||
| Q2 24 | 11.7% | — | ||
| Q1 24 | 11.3% | — |
| Q4 25 | 1.4% | — | ||
| Q3 25 | 0.8% | — | ||
| Q2 25 | 1.1% | — | ||
| Q1 25 | 1.2% | 71.2% | ||
| Q4 24 | 1.4% | -46.4% | ||
| Q3 24 | 1.9% | — | ||
| Q2 24 | 1.7% | — | ||
| Q1 24 | 1.6% | — |
| Q4 25 | $0.39 | — | ||
| Q3 25 | $0.24 | — | ||
| Q2 25 | $0.26 | — | ||
| Q1 25 | $0.30 | $1.90 | ||
| Q4 24 | $0.50 | $-0.15 | ||
| Q3 24 | $0.58 | — | ||
| Q2 24 | $0.40 | — | ||
| Q1 24 | $0.33 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $12.7M | $274.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $86.7M | $350.1M |
| Total Assets | $557.6M | $406.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $12.7M | — | ||
| Q3 25 | $14.8M | — | ||
| Q2 25 | $16.8M | — | ||
| Q1 25 | $12.7M | $274.8M | ||
| Q4 24 | $22.4M | $128.0M | ||
| Q3 24 | $23.7M | — | ||
| Q2 24 | $17.3M | — | ||
| Q1 24 | $32.8M | — |
| Q4 25 | $86.7M | — | ||
| Q3 25 | $82.2M | — | ||
| Q2 25 | $80.0M | — | ||
| Q1 25 | $76.9M | $350.1M | ||
| Q4 24 | $73.6M | $229.0M | ||
| Q3 24 | $68.4M | — | ||
| Q2 24 | $62.1M | — | ||
| Q1 24 | $59.7M | — |
| Q4 25 | $557.6M | — | ||
| Q3 25 | $571.6M | — | ||
| Q2 25 | $570.2M | — | ||
| Q1 25 | $513.9M | $406.9M | ||
| Q4 24 | $475.9M | $271.6M | ||
| Q3 24 | $460.1M | — | ||
| Q2 24 | $429.3M | — | ||
| Q1 24 | $401.3M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $9.8M | $131.8M |
| Free Cash FlowOCF − Capex | $8.7M | $131.7M |
| FCF MarginFCF / Revenue | 3.4% | 83.0% |
| Capex IntensityCapex / Revenue | 0.4% | 0.1% |
| Cash ConversionOCF / Net Profit | 2.77× | 1.17× |
| TTM Free Cash FlowTrailing 4 quarters | $-36.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $9.8M | — | ||
| Q3 25 | $22.8M | — | ||
| Q2 25 | $-28.9M | — | ||
| Q1 25 | $-34.9M | $131.8M | ||
| Q4 24 | $5.5M | $-23.2M | ||
| Q3 24 | $22.9M | — | ||
| Q2 24 | $39.0K | — | ||
| Q1 24 | $-9.3M | — |
| Q4 25 | $8.7M | — | ||
| Q3 25 | $21.4M | — | ||
| Q2 25 | $-31.1M | — | ||
| Q1 25 | $-35.9M | $131.7M | ||
| Q4 24 | $4.8M | $-23.2M | ||
| Q3 24 | $22.3M | — | ||
| Q2 24 | $-2.1M | — | ||
| Q1 24 | $-9.7M | — |
| Q4 25 | 3.4% | — | ||
| Q3 25 | 8.2% | — | ||
| Q2 25 | -13.9% | — | ||
| Q1 25 | -16.0% | 83.0% | ||
| Q4 24 | 1.7% | -102.7% | ||
| Q3 24 | 8.0% | — | ||
| Q2 24 | -1.0% | — | ||
| Q1 24 | -5.1% | — |
| Q4 25 | 0.4% | — | ||
| Q3 25 | 0.5% | — | ||
| Q2 25 | 0.9% | — | ||
| Q1 25 | 0.5% | 0.1% | ||
| Q4 24 | 0.2% | 0.2% | ||
| Q3 24 | 0.2% | — | ||
| Q2 24 | 1.0% | — | ||
| Q1 24 | 0.2% | — |
| Q4 25 | 2.77× | — | ||
| Q3 25 | 10.70× | — | ||
| Q2 25 | -12.24× | — | ||
| Q1 25 | -13.01× | 1.17× | ||
| Q4 24 | 1.33× | — | ||
| Q3 24 | 4.28× | — | ||
| Q2 24 | 0.01× | — | ||
| Q1 24 | -3.12× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
SDHC
| Southeast | $164.7M | 63% |
| Central | $95.8M | 37% |
STOK
Segment breakdown not available.
